Table 3.
Cytokine Modulators: Adjusted Geometric Means and 95% Confidence Intervals Among Categories of Selected Characteristics
| Geometric Mean (95% Confidence Interval)
|
||||||||
|---|---|---|---|---|---|---|---|---|
| Cytokine Modulators | IL-1RA | sIL-1Rlle | sIL-2Rae | sIL-4Re | sIL-6Re | IL-12p40 | sTNF-R1 | sTNF-R2 |
| N above LLD a | 480 | 429 | 427 | 428 | 411 | 615 | 616 | 615 |
| N imputed: MI | 136 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| N imputed: LLD/2 Characteristics | 0 | 0 | 2 | 1 | 0 | 1 | 0 | 1 |
| Age at blood sampling, y b | ||||||||
| 30–45 | 400 (291, 551) | 4800 (4347, 5299) | 478 (430, 532) | 699 (639, 765) | 49307(43823, 55477) | 161(141, 184) | 1141(1060, 1228) | 673(617,735) |
| 46–50 | 538 (358, 809) | 4870(4265, 5561) | 491 (426, 566) | 666(590, 751) | 59981 (51303, 70128) | 188(157, 224) | 1204(1091, 1328) | 737 (656, 828) |
| 51–55 | 276(194, 393) | 5099 (4590, 5664) | 490 (438, 549) | 635 (577, 698) | 55775(49104, 63352) | 162 (140, 188) | 1214(1118, 1319) | 751(681,828) |
| 56–60 | 323(241,431) | 5566(5063, 6119) | 554(500, 613) | 611(561,666) | 58031(51719,65112) | 177 (156, 200) | 1302(1216, 1394) | 768 (709, 832) |
| 60–75 | 345 (262, 455) | 5970(5451, 6539) | 640 (580, 705) | 640 (589, 695) | 62082(55557, 69374) | 173 (154, 194) | 1478(1387, 1575) | 863 (800, 931) |
| P-trend | 0.21 | 0.00 | 0.00 | 0.08 | 0.01 | 0.57 | 0.00 | 0.00 |
| Body Mass Index, kg/m2c | ||||||||
| <25 | 387(317,472) | 4993 (4683, 5324) | 512 (477, 549) | 646 (610, 686) | 52715 (48789, 56958) | 176(162, 192) | 1262(1205, 1322) | 739 (700, 781) |
| 25–29 | 251(192,328) | 5622 (5174, 6108) | 558 (510, 611) | 645 (598, 696) | 59982 (54286, 66275) | 161 (144, 181) | 1220(1146, 1298) | 806 (748, 867) |
| 30–34 | 448 (313, 642) | 5748 (5146, 6420) | 560(496, 631) | 655(592,725) | 60807 (53187, 69520) | 162(139, 188) | 1381(1269, 1504) | 757(685,837) |
| ≥35 | 506 (278, 919) | 5478 (4438, 6761) | 589 (468, 740) | 645 (532, 782) | 69546(53457,90478) | 204(158, 264) | 1632(1416, 1882) | 839 (709, 993) |
| P-trend | 0.62 | 0.02 | 0.08 | 0.90 | 0.01 | 0.87 | 0.00 | 0.15 |
| P-value ≥30 vs. <30 | 0.06 | 0.13 | 0.27 | 0.84 | 0.08 | 0.93 | 0.00 | 0.69 |
| Menopausal status at blood sampling d | ||||||||
| Premenopausal | 307 (215, 439) | 4592(4126,5110) | 460(410, 516) | 649 (588, 715) | 54014 (47501, 61420) | 179 (154, 208) | 1274(1172, 1385) | 742 (672, 819) |
| Postmenopausal | 381 (302, 481) | 5783 (5383, 6213) | 588 (544, 635) | 647 (606, 691) | 58594 (53641, 64004) | 167(152, 183) | 1290(1224, 1360) | 779(732,829) |
| P-value | 0.41 | 0.00 | 0.00 | 0.98 | 0.39 | 0.51 | 0.83 | 0.50 |
| Parity d | ||||||||
| Nulliparous | 309 (221, 432) | 5493 (4863, 6206) | 524 (458, 600) | 652 (583, 728) | 58354 (50588, 67312) | 163(142, 188) | 1235(1144, 1334) | 795(725,872) |
| 1 | 311 (205, 470) | 5692 (4988, 6495) | 494 (427, 572) | 625 (554, 705) | 57722 (49330, 67542) | 156(131, 185) | 1230(1119, 1353) | 730(651,818) |
| 2 | 354 (272, 461) | 5174(4772, 5609) | 545 (499, 596) | 673 (625, 724) | 57052 (51789, 62850) | 168 (150, 188) | 1303(1225, 1385) | 747 (694, 804) |
| 3 | 348 (245, 493) | 4995(4475, 5577) | 541 (479, 611) | 621 (561, 686) | 55593 (48653, 63522) | 171(148, 198) | 1324(1221, 1435) | 759 (689, 836) |
| 4 or more | 417 (250, 693) | 4880(4191, 5682) | 566 (479, 670) | 603 (525, 693) | 53713 (44878, 64288) | 221 (180, 271) | 1287(1150, 1440) | 772 (674, 883) |
| P-trendf | 0.47 | 0.11 | 0.28 | 0.41 | 0.58 | 0.03 | 0.49 | 0.56 |
| P-value parous/nulliparous | 0.37 | 0.46 | 0.79 | 0.82 | 0.63 | 0.50 | 0.30 | 0.44 |
| Family history of breast/ovarian cancer d, e | ||||||||
| No | 345 (291, 408) | 5505 (5181, 5849) | 575 (538, 614) | 676 (641, 714) | 56180 (52631, 59969) | 182(169, 196) | 1323 (1270, 1377) | 785 (747, 824) |
| Yes | 330(231,471) | 5507 (4763, 6368) | 525 (448, 615) | 734 (644, 836) | 54512 (46584, 63790) | 172(147,202) | 1361(1248, 1485) | 808 (728, 897) |
| P-value | 0.83 | 1.00 | 0.30 | 0.26 | 0.73 | 0.53 | 0.56 | 0.62 |
| Use of NSAIDs at blood sampling d, e | ||||||||
| No | 357 (304, 420) | 5609 (5306, 5929) | 560 (527, 595) | 680 (647, 715) | 54106 (50914, 57499) | 184(171, 198) | 1336(1284, 1390) | 783(747,821) |
| Yes | 332 (229, 483) | 4953(4242,5783) | 531 (448, 630) | 655 (569, 754) | 55004 (46325, 65310) | 154(131, 180) | 1257(1151, 1373) | 771 (694, 857) |
| P-value | 0.73 | 0.14 | 0.57 | 0.63 | 0.86 | 0.05 | 0.22 | 0.80 |
| Smoking status at blood sampling d | ||||||||
| Never | 358 (290, 442) | 5167(4837,5519) | 514 (481, 550) | 665 (628, 703) | 54126(49814, 58812) | 179(163, 196) | 1258(1195, 1323) | 743 (701, 789) |
| Former | 324 (237, 443) | 5397(4855,5999) | 568 (510, 633) | 624(570, 682) | 60654 (52942, 69491) | 183 (160, 210) | 1307(1213, 1409) | 869 (796, 948) |
| Current | 337 (233, 488) | 5428 (4829, 6101) | 585 (519, 660) | 689 (624, 761) | 59790 (51297, 69689) | 147(125, 173) | 1310(1198, 1432) | 771(695,855) |
| P-value current vs. never | 0.64 | 0.48 | 0.07 | 0.61 | 0.35 | 0.05 | 0.47 | 0.49 |
| P-value former vs. never | 0.70 | 0.46 | 0.14 | 0.25 | 0.21 | 0.72 | 0.36 | 0.00 |
| 25(OH)Dd | ||||||||
| ≤ 50 nmol/L | 329 (248, 437) | 5558 (5071, 6092) | 541 (494, 593) | 663 (610, 720) | 53340 (48668, 58461) | 167(149, 188) | 1304(1215, 1399) | 743 (684, 806) |
| > 50 nmol/L | 515(357,743) | 5318 (4622, 6119) | 559 (486, 642) | 678 (598, 769) | 60096 (52202, 69184) | 193 (166, 225) | 1361(1242, 1493) | 772 (694, 859) |
| P-value | 0.07 | 0.61 | 0.72 | 0.77 | 0.17 | 0.15 | 0.48 | 0.59 |
Note: NSAIDs: non-steroidal anti-inflammatory drugs, 25(OH)D: 25-hydroxy vitamin D, IL: interleukin, RA: receptor antagonist, Ra: receptor alpha, R: receptor, TNF: tumor necrosis factor All cytokine units are pg/mL.
Number of women for whom the biomarker was above the LLD (fewer women may be included in analyses of characteristics with missing data).
Model adjusted for study (NYUWHS-OVCA, NYUWHS-NHL, ORDET, NSHDS) and BMI
Model adjusted for study (NYUWHS-OVCA, NYUWHS-NHL, ORDET, NSHDS) and age at sampling
Models adjusted for study (NYUWHS-OVCA, NYUWHS-NHL, ORDET, NSHDS), age at sampling, and BMI
sIL-1RII and sIL-4R were not measured in the NYUWHS-NHL study (n=184 subjects). Because sIL-2Ra was measured in the NYUWHS-NHL study using a different manufacturer’s kit and protocol, the NYUWHS-NHL subjects are not included for this marker. sIL-6R values were above the upper limit of detection for 90% of the NYUWHS-NHL samples, thus the NHL subjects are not included for this marker.
P-value for trend among parous women